{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T22:17:29Z","timestamp":1791065849761,"version":"4.1.0"},"reference-count":37,"publisher":"Baishideng Publishing Group Inc.","issue":"42","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["WJG"],"published-print":{"date-parts":[[2008]]},"DOI":"10.3748\/wjg.14.6467","type":"journal-article","created":{"date-parts":[[2008,11,22]],"date-time":"2008-11-22T09:42:39Z","timestamp":1227346959000},"page":"6467","source":"Crossref","is-referenced-by-count":23,"title":["Antiviral therapy in hepatitis C virus cirrhotic patients in compensated and decompensated condition"],"prefix":"10.3748","volume":"14","author":[{"given":"Angelo","family":"Iacobellis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Ippolito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Andriulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2060","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Fattovich G, Giustina G, Degos F, Diodati G, Tremolada F, Nevens F, Almasio P, Solinas A, Brouwer JT, Thomas H. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol 1997;27:201-205.","DOI":"10.1016\/S0168-8278(97)80302-9"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003;9:331-338.","DOI":"10.1053\/jlts.2003.50073"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.","DOI":"10.1056\/NEJMoa020047"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965.","DOI":"10.1016\/S0140-6736(01)06102-5"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Di Marco V, Almasio PL, Ferraro D, Calvaruso V, Alaimo G, Peralta S, Di Stefano R, Craxi A. Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial. J Hepatol 2007;47:484-491.","DOI":"10.1016\/j.jhep.2007.04.020"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Yoshida H, Arakawa Y, Sata M, Nishiguchi S, Yano M, Fujiyama S, Yamada G, Yokosuka O, Shiratori Y, Omata M. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology 2002;123:483-491.","DOI":"10.1053\/gast.2002.34785"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Peck-Radosavljevic M, Wichlas M, Homoncik-Kraml M, Kreil A, Hofer H, Jessner W, Gangl A, Ferenci P. Rapid suppression of hematopoiesis by standard or pegylated interferon-alpha. Gastroenterology 2002;123:141-151.","DOI":"10.1053\/gast.2002.34175"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Soza A, Everhart JE, Ghany MG, Doo E, Heller T, Promrat K, Park Y, Liang TJ, Hoofnagle JH. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology 2002;36:1273-1279.","DOI":"10.1053\/jhep.2002.36502"},{"key":"ref9","unstructured":"Almasio PL, Venezia G, Craxi A. The impact of antiviral therapy on the course of chronic HCV infection. A systematic review. Panminerva Med 2003;45:175-182."},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Juarez-Navarro A, Vera-de-Leon L, Navarro JM, Chirino-Sprung R, Diaz-Hernandez M, Casillas-Davila L, Dehesa-Violante M. Incidence and severity of infections according to the development of neutropenia during combined therapy with pegylated interferon-alpha2a plus ribavirin in chronic hepatitis C infection. Methods Find Exp Clin Pharmacol 2005;27:317-322.","DOI":"10.1358\/mf.2005.27.5.908646"},{"key":"ref11","unstructured":"Manfredi R, Sabbatani S. Multiple, repeated filgrastim treatment cycles to recover severe, recurring pegylated interferon-related neutropenia. Hepatogastroenterology 2007;54:4."},{"key":"ref12","unstructured":"Sharvadze L, Gochitashvili N, Tophuria A, Bolokadze N, Tsertsvadze T. IFN\/RBV treatment induced neutropenia and its correction with neupogen in patients with hepatitis C. Georgian Med News 2007;54:52-55."},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Sulkowski MS, Wasserman R, Brooks L, Ball L, Gish R. Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. J Viral Hepat 2004;11:243-250.","DOI":"10.1111\/j.1365-2893.2004.00490.x"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003;38:645-652.","DOI":"10.1053\/jhep.2003.50364"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, Dienstag J, Lee WM, Mak C, Garaud JJ. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002;123:1061-1069.","DOI":"10.1053\/gast.2002.35950"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-355.","DOI":"10.7326\/0003-4819-140-5-200403020-00010"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Spivak JL. The blood in systemic disorders. Lancet 2000;355:1707-1712.","DOI":"10.1016\/S0140-6736(00)02249-2"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Barosi G. Inadequate erythropoietin response to anemia: definition and clinical relevance. Ann Hematol 1994;68:215-223.","DOI":"10.1007\/BF01737420"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"McHutchison JG, Manns MP, Brown RS Jr, Reddy KR, Shiffman ML, Wong JB. Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy. Am J Gastroenterol 2007;102:880-889.","DOI":"10.1111\/j.1572-0241.2007.01139.x"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Afdhal NH, Dieterich DT, Pockros PJ, Schiff ER, Shiffman ML, Sulkowski MS, Wright T, Younossi Z, Goon BL, Tang KL. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 2004;126:1302-1311.","DOI":"10.1053\/j.gastro.2004.01.027"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Pol S, Carnot F, Nalpas B, Lagneau JL, Fontaine H, Serpaggi J, Serfaty L, Bedossa P, Brechot C. Reversibility of hepatitis C virus-related cirrhosis. Hum Pathol 2004;35:107-112.","DOI":"10.1016\/j.humpath.2003.08.012"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, Kuroki T, Nishiguchi S, Sata M, Yamada G. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000;132:517-524.","DOI":"10.7326\/0003-4819-132-7-200004040-00002"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Dufour JF, DeLellis R, Kaplan MM. Regression of hepatic fibrosis in hepatitis C with long-term interferon treatment. Dig Dis Sci 1998;43:2573-2576.","DOI":"10.1023\/A:1026601904609"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, Ling MH, Albrecht J. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002;122:1303-1313.","DOI":"10.1053\/gast.2002.33023"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Benvegnu L, Chemello L, Noventa F, Fattovich G, Pontisso P, Alberti A. Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. Cancer 1998;83:901-909.","DOI":"10.1002\/(SICI)1097-0142(19980901)83:5<901::AID-CNCR15>3.0.CO;2-Z"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Yoshida H, Arakawa Y, Sata M, Nishiguchi S, Yano M, Fujiyama S, Yamada G, Yokosuka O, Shiratori Y, Omata M. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology 2002;123:483-491.","DOI":"10.1053\/gast.2002.34785"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, Reindollar R, Reddy RK, Wright TL, Lin A. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000;343:1673-1680.","DOI":"10.1056\/NEJM200012073432302"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnu L, Mazzella G, Ascione A, Santantonio T, Piccinino F, Andreone P. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007;45:579-587.","DOI":"10.1002\/hep.21492"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Jacob AI, Goldberg PK, Bloom N, Degenshein GA, Kozinn PJ. Endotoxin and bacteria in portal blood. Gastroenterology 1977;72:1268-1270.","DOI":"10.1016\/S0016-5085(77)80025-5"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Iwasaki Y, Ikeda H, Araki Y, Osawa T, Kita K, Ando M, Shimoe T, Takaguchi K, Hashimoto N, Kobatake T. Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatology 2006;43:54-63.","DOI":"10.1002\/hep.20984"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Romero-Gomez M, Del Mar Viloria M, Andrade RJ, Salmeron J, Diago M, Fernandez-Rodriguez CM, Corpas R, Cruz M, Grande L, Vazquez L. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005;128:636-641.","DOI":"10.1053\/j.gastro.2004.12.049"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Everson GT, Trotter J, Forman L, Kugelmas M, Halprin A, Fey B, Ray C. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005;42:255-262.","DOI":"10.1002\/hep.20793"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Iacobellis A, Siciliano M, Perri F, Annicchiarico BE, Leandro G, Caruso N, Accadia L, Bombardieri G, Andriulli A. Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study. J Hepatol 2007;46:206-212.","DOI":"10.1016\/j.jhep.2006.08.020"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Forns X, Garcia-Retortillo M, Serrano T, Feliu A, Suarez F, de la Mata M, Garcia-Valdecasas JC, Navasa M, Rimola A, Rodes J. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003;39:389-396.","DOI":"10.1016\/S0168-8278(03)00310-6"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Thomas RM, Brems JJ, Guzman-Hartman G, Yong S, Cavaliere P, Van Thiel DH. Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation. Liver Transpl 2003;9:905-915.","DOI":"10.1053\/jlts.2003.50166"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Crippin JS, McCashland T, Terrault N, Sheiner P, Charlton MR. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002;8:350-355.","DOI":"10.1053\/jlts.2002.31748"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Everson GT. Treatment of patients with hepatitis C virus on the waiting list. Liver Transpl 2003;9:S90-S94.","DOI":"10.1053\/jlts.2003.50247"}],"container-title":["World Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.wjgnet.com\/1007-9327\/full\/v14\/i42\/6467.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,10]],"date-time":"2020-05-10T18:50:38Z","timestamp":1589136638000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.wjgnet.com\/1007-9327\/full\/v14\/i42\/6467.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008]]},"references-count":37,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.3748\/wjg.14.6467","relation":{},"ISSN":["1007-9327"],"issn-type":[{"value":"1007-9327","type":"print"}],"subject":[],"published":{"date-parts":[[2008]]}}}